Evidence map›Paper›PMID 40709109›Full record

ArticleCureus2025

Association Between Metabolic Syndrome and Choledocholithiasis: An Observational, Analytical, Retrospective Cross-Sectional Study Conducted at a Second-Level Hospital in Ciudad Juárez From January 2024 to February 2025.

Yareli Lizbeth Rojas Salazar, Emiliano Gomez Montanez, Jorge Gustavo Rojas Salazar

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yareli Lizbeth Rojas SalazarCancer Functional Genomics Laboratory, National Institute of Genomic Medicine, Mexico City, MEX.
Emiliano Gomez MontanezCancer Functional Genomics Laboratory, National Institute of Genomic Medicine, Mexico City, MEX.
Jorge Gustavo Rojas SalazarGeneral Surgery, Autonomous University of Ciudad Juárez, Ciudad Juárez, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Metabolic syndrome (MS) is a disorder that groups conditions such as central obesity, hypertension, dyslipidemia, and hyperglycemia, and it is also associated with cardiovascular diseases and type 2 diabetes mellitus, in which an increase in biliary diseases such as choledocholithiasis, characterized by the presence of stones in the common bile duct, has been observed. This association may be explained by metabolic alterations that lead to increased cholesterol saturation in bile and impaired gallbladder motility due to insulin resistance, both of which contribute to the formation of stones. This study aims to investigate the relationship between MS and choledocholithiasis in patients treated at a second-level hospital in Ciudad Juárez between January 2024 and February 2025. Materials and methods Observational, analytical, retrospective, cross-sectional study with 59 patients over 17 years of age who were divided into two groups: with choledocholithiasis (29, 49%) and without choledocholithiasis (30, 51%). For each group, the ATP III diagnostic criteria for MS were evaluated. For statistical analysis, chi-square, Fisher's exact test, and odds ratio were used. Results The presence of MS was significantly associated with choledocholithiasis (p=0.002; OR=5.83, 95% CI: 1.93-19.33); BMI over 30 was the only MS component with a statistically significant association in both patients with and without choledocholithiasis (p=0.0016 and p=0.008, respectively). Conclusions The presence of MS is a risk factor for the development of choledocholithiasis in the studied population. A high BMI is confirmed as a relevant risk factor. These findings provide useful local evidence for the development of preventive strategies and clinical management.

Indexed as

body mass indexcholedocholithiasismetabolic syndromeobesityrisk factors

Identifiers

PMID40709109
PMCPMC12287678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.